AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05741593 — intervention group
Intervention type: OTHER
Intervention: Analysis of the verbatim from the transcription of the recorded interviews.
Description: recorded semi-structured interviews between the patients and the pharmacist
Study NCT06726889 — intervention group
Intervention type: BEHAVIORAL
Intervention: Standard care
Description: Patient will not receive any additional interventions
Study NCT05612022 — intervention group
Intervention type: PROCEDURE
Intervention: AVF creation
Description: AVF is surgically created in the forearm by an anastomosis between a vein and an artery
Study NCT05612022 — intervention group
Intervention type: PROCEDURE
Intervention: AVG creation
Description: Surgery is done using an artificial plastic tube that connects an artery to a vein
Study NCT05039853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief cognitive task-based intervention
Description: Memory reminder procedure, playing the computer game, Tetris , on a smart-device using mental rotation +/- Boosters
Study NCT05039853 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo activity
Description: Listening to a pod-cast on a smart-device for approximately 15 minutes.
Study NCT04606914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirvetuximab soravtansine (MIRV; IMGN853)
Description: Mirvetuximab soravtansine (also known as IMGN853 and MIRV) is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor α (FRα, the protein product of the folate receptor 1 \[FOLR1\] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridin-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB) linker. FRα is a glycosyl-phosphatidylinositol (GPI)-linked protein, which shows limited normal tissue expression and high expression on the surface of solid tumors, particularly epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (referenced herein collectively as EOC), endometrial cancer, non-small cell lung cancer (NSCLC), and renal cell cancer.
Study NCT05251311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Risk Screening Tool
Description: Investigators will use an adapted version of the evidence-based WE CARE screening tool, which assesses need in the 5 domains most frequently requested by our patient population: housing, transportation, child care, food security, and household heat and electricity. This tool was selected as it is evidence-based, takes fewer than 5 minutes to complete, is written at a 3rd grade reading level, and allows for differentiation between social risk and caregiver desire for assistance, as well as areas of emergency need.
Study NCT05251311 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Resource Map
Description: All participants will receive access to an electronic, geographically searchable resource map hosted on Aunt Bertha
Study NCT05251311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Resource Map
Description: All participants will receive access to an electronic, geographically searchable resource map hosted on Aunt Bertha
Study NCT05251311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resource Menu
Description: Participants randomized to this experimental arm will receive a social resource menu tool, which assess desire for social resources.
Study NCT05177211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib Pill
Description: Participants will be given Fedratinib at a dose of 400 mg PO once daily (4-100 mg capsules). Fedratinib can be given at any time during the day, but patients are advised to take the dose at the same approximate time every day.
Study NCT04942327 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interview
Description: This will be evaluated through a specific questionnaire that will be systematically gone over with the participants during an interview in the first and third phases.
Study NCT05679557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perioperative geriatric assessment and intervention
Description: The intervention will comprise a preoperative, thorough geriatric, multidisciplinary assessment (CGA) and tailored interventions, focused on optimizing health issues of expected importance in further course of surgery. Furthermore, postoperative ward rounds by a geriatric team will be conducted. Thus, the course of treatment for each patient will be a close interdisciplinary collaboration.
Study NCT06048497 — intervention group
Intervention type: DEVICE
Intervention: Corrected carotid flow time measurement guided fluid preload
Description: Preoperative FTcs of pregnant women who underwent C/S operation were measured, and those below the cut-off value (327 ms) determined in previous studies were preloaded with Ringer Lactate until FTc was > 327 ms.
Study NCT05407766 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OSSM-001
Description: Single injection of OSSM-001 at dose of 100M or 300M cells
Study NCT05407766 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single injection of placebo (saline)
Study NCT05157997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casirivimab and Imdevimab Antibody Cocktail
Description: The study will utilize REGEN-COV 8,000mg (4,000 mg of each monoclonal antibody) given as IV infusion on day of transplant and 2400mg (1,200 mg of each monoclonal antibody) on post-operative day 1.
Study NCT05434754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eHealth Tool
Description: text messaging algorithm
Study NCT05642975 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional Block Comparison
Description: Comparing postoperative pain and opioid consumption in groups
Study NCT05253651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300mg given by mouth (orally) twice daily
Study NCT05253651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 8mg/kg loading dose will be given into the vein (IV; intravenously) on Cycle 1 day 1, followed by 6mg/kg given by IV every 3 weeks thereafter.
Study NCT05253651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: 5mg/kg given by IV every 2 weeks
Study NCT05253651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: 400mg/m2 loading dose will be given by IV on Cycle 1 day 1, followed by 250mg/m2 given by IV weekly
Study NCT05253651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: 85mg/m2 given by IV every 2 weeks. Component of mFOLFOX6.
Study NCT05938465 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EXE-346
Description: EXE-346 contains a proprietary, fixed-dose, lyophilized blend of 8 strains of gram positive, lactic acid bacteria. EXE-346 excipients are maltose and silicon dioxide.
Study NCT05938465 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains excipients maltose and silicon dioxide.
Study NCT05253651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 85mg/m2 given by IV every 2 weeks. Component of mFOLFOX6.
Study NCT05253651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin
Description: 400mg/ m2 given by IV every 2 weeks. Component of mFOLFOX6.
Study NCT05253651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: 400mg/ m2 given by IV every 2 weeks. Component of mFOLFOX6.
Study NCT05253651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levoleucovorin
Description: 200mg/ m2 given by IV every 2 weeks. May be given in place of leucovorin. Component of mFOLFOX6.
Study NCT05253651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levoleucovorin
Description: 200mg/ m2 given by IV every 2 weeks. May be given in place of leucovorin. Component of mFOLFOX6.
Study NCT05253651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: 400mg/m2 given by IV bolus then 2400mg/m2 given by continuous IV infusion (over 46-48 hours) every 2 weeks. Component of mFOLFOX6.
Study NCT05253651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 400mg/m2 given by IV bolus then 2400mg/m2 given by continuous IV infusion (over 46-48 hours) every 2 weeks. Component of mFOLFOX6.
Study NCT04869514 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal manipulation
Description: intervention will consist of either lumbar manipulation, thoracic manipulation or lumbar mobilisation
Study NCT04869514 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: spinal manipulation
Description: intervention will consist of either lumbar manipulation, thoracic manipulation or lumbar mobilisation
Study NCT04562090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: Mirabegron was administered as single oral dose of 25 mg or 50 mg sustained-release tablet
Study NCT06642688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sacroiliac Joint Manipulation
Description: The patient was asked to tie his arms while he was in the side lying position. The patient's upper knee was flexed and positioned such that it was placed in the popliteal fossa of the lower knee, while the lower knee was in full extension. Pushing maneuver was performed with HVLA from posterior to anterior and from medial to lateral with pelvic rotation. The contact point of the sacroiliac joint was PSIS.
Study NCT06642688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Spine Manipulation
Description: Cervical SM was applied supine to restrictions found on motion palpation, according to the technique described by Bergmann and Peterson28 The participant's head and neck were simultaneously rotated and laterally flexed over the contact point-specifically, the posterior supramastoid groove or zygomatic arch (C0-C1), the posterior aspect of the transverse process (C1-C2), or the posterior articular pillar of superior vertebrae (C2-C7) -to the end of passive ROM. Thereafter, a high-velocity, low-amplitude thrust was delivered in the direction of restricted movement. Participants with more ROM restriction in the lateral plane were given more lateral-to-medial directed thrusts; participants with more restriction in rotation were given thrusts in the direction of restricted axial rotation; and participants with more restriction in extension were given more anteriorly directed thrusts.
Study NCT05384223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RRFT (Risk Reduction through Family Therapy)
Description: RRFT is an adaptation and integration of existing empirically-supported interventions with similar theoretical rationales targeting similar populations, particularly Multisystemic Therapy principles (MST)for adolescent SUP and Trauma Focused-Cognitive Behavioral Therapy (TF-CBT) components for PTSD in youth. RRFT consists of seven primary components: Psychoeducation and Engagement, Coping, Family Communication, Substance Use, PTSD, Healthy Dating and Sexual Decision-Making, and Revictimization Risk Reduction.
Study NCT05384223 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ENCOMPASS (Integrated Treatment for Adolescents and Young Adults)
Description: Encompass is currently a research to practice treatment for adolescents with co-occurring substance use disorders and mental health problems and is used as the standard treatment in the target study settings.
Study NCT04511468 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc, Chromium, Vitamin C, and Copper Supplementation
Description: Combination of mineral and vitamin supplementation that consist of Zinc, Chromium, Vitamin C, and Copper
Study NCT04511468 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard healthy lifestyle intervention
Description: Standard healthy lifestyle intervention will follow the Guidelines on the Management and Prevention of Prediabetes by the Indonesian Ministry of Healthy and the Indonesian Diabetes Association.
Study NCT04511468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard healthy lifestyle intervention
Description: Standard healthy lifestyle intervention will follow the Guidelines on the Management and Prevention of Prediabetes by the Indonesian Ministry of Healthy and the Indonesian Diabetes Association.
Study NCT04511468 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with inactive ingredients
Study NCT05852470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clareon Vivity/Vivity Toric Extended Vision IOL
Description: Extended vision intraocular lens implanted in the capsular bag of the eye during cataract surgery. IOLs are intended for long term use over the lifetime of the cataract patient.
Study NCT05852470 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clareon Monofocal/Clareon Toric IOL
Description: Single vision intraocular lens implanted in the capsular bag of the eye during cataract surgery. IOLs are intended for long term use over the lifetime of the cataract patient.
Study NCT06528184 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Self-sampled HPV DNA testing
Description: Participants will be offered HPV DNA testing done through self-sampling (using self-sampling HPV DNA kits to obtain a mid-vaginal swab)
Study NCT06528184 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinician-sampled HPV DNA test
Description: Participants will be offered HPV DNA testing through clinician sampling (clinician-sampling (speculum examination by a nurse to obtain a cervical swab)
Study NCT06528184 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Clinician-sampled HPV DNA test
Description: Participants will be offered HPV DNA testing through clinician sampling (clinician-sampling (speculum examination by a nurse to obtain a cervical swab)
Study NCT06514443 — intervention group
Intervention type: OTHER
Intervention: survey
Description: survey exploring barriers and faciltiators for physical activity
Study NCT06074757 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fulvestrant injection
Description: phosphate ester of fulvestrant for test arm
Study NCT06074757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant injection
Description: phosphate ester of fulvestrant for test arm
Study NCT05912452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percussion Massage Therapy
Description: Individuals who receive percussion massage therapy will be treated with a 5-minute medium-frequency percussion massage on the deltoid muscle group every other day. Percussion massage therapy will be applied in a total of 10 sessions and will be completed in 20 days.
Study NCT05912452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: the Kinesiotape group; Kinesiotape banding will be done with 25% tension by applying a Y band to the deltoid muscle group. After the application, the Kinesio band will stay on the participant for 2 days. The next day, the participant will rest. This cycle will be repeated for 20 days.
Study NCT05912452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Description: Dynamic stretching exercises will be applied to the shoulder flexor and abductor muscle groups in the Dynamic Stretching Group with 10 repetitions. As in percussion massage therapy, these exercises will be performed under the supervision of a physiotherapist every other day. The application will continue for 20 days.
Study NCT06094855 — intervention group
Intervention type: OTHER
Intervention: 20 minutes of biking on a stationary recumbent bicycle with and without a cooling vest
Description: 2 bouts of 20 minutes of pedaling on a stationary recumbent bicycle, 1-2 weeks apart. Subjects will be cooled for one of the bouts and uncooled for the other.
Study NCT06468930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level light therapy (LLLT)
Description: LLLT therapy will be delivered using the Light Modulation® special facial mask (Espansione Marketing S.p.A., Bologna, Italy) which will be placed on the participant's face for 15 minutes. The mask has the shape of a half-face and will emit a red light in an LED system. The device has an emission power of 100 The mask has the shape of a half-face and will emit a red light in a light-emitting diode (LED) system. The device has an emission power of 100 milliwatts per square centimeter.
Study NCT06468930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL)
Description: The IPL therapy will be performed using the Eye-light® with Optimal Power Energy® (Espansione Marketing S.p.A., Bologna, Italy), which emits the light at a wavelength of 600 nm IPL system with fluence ranging from 10 to 16 J/cm2 per eye depending on the Fitzpatrick skin scale. During IPL treatment 5 flashes of light will be applied to the skin around the eye using a handheld device; 3 along the inferior orbital rim, 1 at the lateral canthus, and 1 applied horizontally along the inferior orbital rim
Study NCT06468930 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intense pulsed light (IPL)
Description: The IPL therapy will be performed using the Eye-light® with Optimal Power Energy® (Espansione Marketing S.p.A., Bologna, Italy), which emits the light at a wavelength of 600 nm IPL system with fluence ranging from 10 to 16 J/cm2 per eye depending on the Fitzpatrick skin scale. During IPL treatment 5 flashes of light will be applied to the skin around the eye using a handheld device; 3 along the inferior orbital rim, 1 at the lateral canthus, and 1 applied horizontally along the inferior orbital rim
Study NCT05682248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation
Study NCT05682248 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Transcranial magnetic stimulation
Description: Sham Transcranial magnetic stimulation
Study NCT04912011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canrenoate Potassium
Description: Intervention: 200 mg of Canrenoate potassium in 100 ml 0,9% NaCl, intravenously twice a day for 7 days.
Study NCT04912011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo: 100 ml 0,9% NaCl, intravenously twice a day for 7 days.
Study NCT05571579 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood and/or csf collection
Description: blood and/or collection~Only once :~* 1 tube of blood of 4 mL on dry tube with or without gel,~* 2 tubes of blood of 4 mL on EDTA tube, If CSF collected for diagnosis is available, it can be sent for storage in the collection.
Study NCT04903093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib tablet
Description: Single dose of abrocitinib 200 mg tablet will be administered after an overnight fast of at least 10 hours.
Study NCT04903093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib Suspension F1
Description: Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.
Study NCT04903093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib Suspension F2
Description: Single dose of abrocitinib 200 mg oral suspension formulation 2 will be administered after an overnight fast of at least 10 hours.
Study NCT04903093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib Suspension F3
Description: Single dose of abrocitinib 200 mg oral suspension formulation 3 will be administered after an overnight fast of at least 10 hours.
Study NCT04903093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib Suspension F4
Description: Single dose of abrocitinib 200 mg oral suspension formulation 4 will be administered after an overnight fast of at least 10 hours.
Study NCT04903093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib Suspension F5
Description: Single dose of abrocitinib 200 mg oral suspension formulation 5 will be administered after an overnight fast of at least 10 hours.
Study NCT04903093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib Suspension F6
Description: Single dose of abrocitinib 200 mg oral suspension formulation 6 will be administered after an overnight fast of at least 10 hours.
Study NCT04903093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.
Study NCT05697757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Lighting
Description: This will be an eighteen-hour lighting scheme that includes three modes: morning (6:00 - 12:00), afternoon (12:00 - 18:00), and evening (18:00 - 24:00). It mimics natural lighting by providing blue-enriched high-intensity lighting in the morning and neutral white medium-intensity lighting in the afternoon to maintain alertness without exerting substantial circadian effects. The biodynamic lighting will provide yellowish low-intensity lighting in the evening to minimize any circadian effect.
Study NCT05697757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Lighting
Description: We will include an active placebo condition that will be a whole-day lighting scheme with constant color and brightness from morning to evening. The numbers of CCT and illuminance levels are selected based on the average room lighting